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Background
Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been stud-
ied in a broad population of patients at high risk for atherothrombotic events.
Methods
We randomly assigned 15,603 patients with either clinically evident cardiovascular 
disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose 
aspirin (75 to 162 mg per day) or placebo plus low-dose aspirin and followed them 
for a median of 28 months. The primary efficacy end point was a composite of 
myocardial infarction, stroke, or death from cardiovascular causes.
Results
The rate of the primary efficacy end point was 6.8 percent with clopidogrel plus aspi-
rin and 7.3 percent with placebo plus aspirin (relative risk, 0.93; 95 percent confidence 
interval, 0.83 to 1.05; P = 0.22). The respective rate of the principal secondary efficacy 
end point, which included hospitalizations for ischemic events, was 16.7 percent and 
17.9 percent (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.995; P = 0.04), 
and the rate of severe bleeding was 1.7 percent and 1.3 percent (relative risk, 1.25; 95 
percent confidence interval, 0.97 to 1.61 percent; P = 0.09). The rate of the primary end 
point among patients with multiple risk factors was 6.6 percent with clopidogrel and 
5.5 percent with placebo (relative risk, 1.2; 95 percent confidence interval, 0.91 to 
1.59; P = 0.20) and the rate of death from cardiovascular causes also was higher with 
clopidogrel (3.9 percent vs. 2.2 percent, P = 0.01). In the subgroup with clinically evi-
dent atherothrombosis, the rate was 6.9 percent with clopidogrel and 7.9 percent with 
placebo (relative risk, 0.88; 95 percent confidence interval, 0.77 to 0.998; P = 0.046).
Conclusions
In this trial, there was a suggestion of benefit with clopidogrel treatment in patients 
with symptomatic atherothrombosis and a suggestion of harm in patients with mul-
tiple risk factors. Overall, clopidogrel plus aspirin was not significantly more effective 
than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from 
cardiovascular causes. (ClinicalTrials.gov number, NCT00050817.)
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A therosclerotic vascular disease has a propensity to engender arterial throm-bosis, a sequence that has been character-
ized as an “atherothrombotic” process.1,2 Collec-
tively, atherothrombotic disorders of the coro nary, 
cerebrovascular, and peripheral arterial circula-
tion are the leading cause of death and disability 
in the world.3 Their prevalence is increasing; they 
are significantly undertreated, and better means 
of prevention are needed.4
Platelets have been shown to play a central 
role in the pathogenesis of atherothrombosis.1,2 
Low-dose aspirin has been shown to reduce ische-
mic outcomes in patients above a certain risk 
threshold.5 However, aspirin alone in many in-
stances is not sufficient to prevent ischemic events 
in patients at high risk. Furthermore, aspirin in-
hibits only the cyclooxygenase pathway, leaving 
the adenosine diphosphate P2Y12 receptor unaf-
fected. Dual antiplatelet therapy with clopidogrel 
(Plavix, Sanofi-Aventis), a P2Y12-receptor antago-
nist, plus aspirin has been shown to reduce is-
che mic events in patients with unstable angina, 
myocardial infarction without ST-segment eleva-
tion, or myocardial infarction with ST-segment 
elevation, as well as those undergoing angioplasty 
and stenting.6-9
Accordingly, we tested the hypothesis that long-
term treatment with a combination of clopidogrel 
plus aspirin may provide greater protection against 
cardiovascular events than aspirin alone in a broad 
population of patients at high risk.
Me thods
Trial Design
The Clopidogrel for High Atherothrombotic Risk 
and Ischemic Stabilization, Management, and 
Avoidance (CHARISMA) trial was a prospective, 
multicenter, randomized, double-blind, placebo-
controlled study of the efficacy and safety of 
clopidogrel plus aspirin as compared with aspi-
rin alone in patients at high risk for a cardiovas-
cular event. The details of the trial design have 
been published previously.10 The trial was approved 
by the institutional ethics committee of each par-
ticipating institution as well as the appropriate 
national ethics committees.
The trial was designed by Dr. Topol, who was 
responsible for obtaining funding and executing 
the trial, and it was planned and conducted by the 
executive committee, with extensive review of the 
data for its interpretation. The trial was managed 
by the Cleveland Clinic Cardiovascular Coordinat-
ing Center and by the national coordinators in 
each country in which patients were enrolled. Data 
collection and entry were performed by the spon-
sor and cosponsor. The locked, cleaned database 
was transferred to the Cleveland Clinic Cardiovas-
cular Coordinating Center, where data analysis 
was performed. Dr. Bhatt prepared the first draft 
of the manuscript, and the executive committee 
helped to revise it. Dr. Topol had full access to 
an independent database for any query regarding 
the analyses and assumes responsibility for the 
integrity of the data.
Funding for the CHARISMA trial was pro-
vided by Sanofi-Aventis and Bristol-Myers Squibb. 
The sponsor and cosponsor had advisory input 
in the design of the study, had nonvoting input 
in the executive committee, and were responsible 
for auditing at individual study sites. The execu-
tive committee bears complete responsibility for 
the analysis of the results, the veracity and com-
pleteness of the reporting, and the writing of the 
manuscript; the sponsors did have the opportu-
nity to review the manuscript.
Patients
Patients were eligible to enroll in the trial if they 
were 45 years of age or older and had one of the 
following conditions: multiple atherothrombotic 
risk factors, documented coronary disease, docu-
mented cerebrovascular disease, or documented 
symptomatic peripheral arterial disease. The in-
clusion criteria for those with multiple risk fac-
tors and for those with established vascular dis-
ease are shown in Table 1.
Patients were excluded from the trial if they 
were taking oral antithrombotic medications or 
nonsteroidal antiinflammatory drugs on a long-
term basis (although cyclooxygenase-2 inhibitors 
were permitted). Patients were also excluded if, 
in the judgment of the investigator, they had es-
tablished indications for clopidogrel therapy (such 
as a recent acute coronary syndrome). Patients who 
were scheduled to undergo a revascularization 
were not allowed to enroll until the procedure 
had been completed; such patients were excluded 
if they were considered to require clopidogrel af-
ter revascularization.
Trial Procedures
After providing written informed consent, pa-
tients were randomly assigned either to clopido-
grel (75 mg per day) plus low-dose aspirin (75 to 
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162 mg per day) or to placebo plus low-dose aspi-
rin. Study-drug assignment was performed central-
ly by an interactive voice-response system on the 
basis of a preestablished randomization scheme, 
stratified according to site. All patients also re-
ceived standard therapy as appropriate (e.g., statins 
or beta-blockers) at the discretion of the investi-
gator and other responsible clinicians. The use of 
appropriate background therapy was emphasized 
to the investigators, who were provided with in-
ternational guidelines.
Follow-up evaluations were performed at one 
month, three months, and six months and every 
six months thereafter until the end of the trial. At 
these visits, patients’ compliance was assessed, 
standard medication was adjusted as appropriate, 
and all interventions, outcome events, and adverse 
events were recorded. According to the power cal-
culations described below and the event-driven 
design of the trial, all patients were followed un-
til a common study end date based on the pre-
specified target of 1040 primary efficacy end 
points was reached.
Table 1. Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established 
Cardiovascular Disease.
Patients and Criteria
Clopidogrel 
plus Aspirin
Placebo 
plus Aspirin 
no. of patients (%)
Patients with multiple atherothrombotic risk factors* 1659 1625
Major risk factors 1535 (92.5) 1490 (91.7)
Type 1 or 2 diabetes (with drug therapy) 1360 (82.0) 1295 (79.7)
Diabetic nephropathy 716 (43.2) 687 (42.3)
Ankle–brachial index <0.9 94 (5.7) 92 (5.7)
Asymptomatic carotid stenosis ≥70% of luminal diameter 123 (7.4) 132 (8.1)
≥1 Carotid plaque, as evidenced by intima–media thickness 198 (11.9) 213 (13.1)
Minor risk factors 1474 (88.8 ) 1454 (89.5)
Systolic blood pressure ≥150 mm Hg, despite therapy for at least 3 mo 809 (48.8) 744 (45.8)
Primary hypercholesterolemia 993 (59.9) 1030 (63.4)
Current smoking >15 cigarettes/day 284 (17.1) 271 (16.7)
Male sex and age ≥65 yr or female sex and age ≥70 yr 841 (50.7) 853 (52.5)
Patients with established cardiovascular disease† 6062 6091
Documented coronary disease 2892 (47.7) 2943 (48.3)
Angina with documented multivessel coronary disease 888 (14.6) 885 (14.5)
History of multivessel percutaneous coronary intervention 398 (6.6) 434 (7.1)
History of multivessel coronary-artery bypass grafting 736 (12.1) 733 (12.0)
Myocardial infarction 1903 (31.4) 1943 (31.9)
Documented cerebrovascular disease 2157 (35.6) 2163 (35.5)
Transient ischemic attack during previous 5 yr 617 (10.2) 616 (10.1)
Ischemic stroke during previous 5 yr 1634 (27.0) 1611 (26.4)
Documented symptomatic peripheral arterial disease 1418 (23.4) 1420 (23.3)
Current intermittent claudication and ankle–brachial index ≤0.85 885 (14.6) 892 (14.6)
History of intermittent claudication and previous intervention 
(e.g., amputation, peripheral bypass, or angioplasty)
835 (13.8) 801 (13.2)
* Data on the other 166 patients enrolled but not categorized were not adequately differentiated on the basis of medical 
records. To meet the criterion for enrollment on the basis of multiple risk factors, patients were required to have two 
major or three minor or one major and two minor atherothrombotic risk factors.
† To meet the criterion for enrollment on the basis of established cardiovascular disease, patients were required to have 
one of the listed conditions.
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End Points
All primary trial end points were adjudicated by 
the clinical events committee, whose members 
were unaware of patients’ treatment assignments. 
The primary efficacy end point was the first oc-
currence of myocardial infarction, stroke (of any 
cause), or death from cardiovascular causes (in-
cluding hemorrhage). The principal secondary ef-
ficacy end point was the first occurrence of myo-
cardial infarction, stroke, death from cardiovascular 
causes, or hospitalization for unstable angina, a 
transient ischemic attack, or a revascularization 
procedure (coronary, cerebral, or peripheral). Oth-
er efficacy end points included death from any 
cause and death from cardiovascular causes as well 
as myocardial infarction, ischemic stroke, any 
stroke, and hospitalization for unstable angina, 
transient ischemic attack, or revascularization, con-
sidered separately.
The primary safety end point was severe bleed-
ing, according to the Global Utilization of Strep-
tokinase and Tissue Plasminogen Activator for 
Occluded Coronary Arteries (GUSTO) definition, 
which includes fatal bleeding and intracranial 
hemorrhage, or bleeding that caused hemody-
namic compromise requiring blood or fluid re-
placement, inotropic support, or surgical interven-
tion.11 Moderate bleeding according to the GUSTO 
criteria (bleeding that led to transfusion but did 
not meet the criteria for severe bleeding) was also 
examined, as were fatal bleeding and primary in-
tracranial hemorrhage.
Analyses of the primary end point were also 
performed in several prospectively defined sub-
groups. The subgroups included symptomatic pa-
tients (defined as patients enrolled on the basis of 
established cardiovascular disease) as compared 
with asymptomatic patients (those enrolled on 
the basis of multiple atherothrombotic risk fac-
tors), as well as patients with and those without 
a history of diabetes, hypertension, hypercholes-
terolemia, peripheral arterial disease, prior car-
diac or vascular surgery, prior myocardial infarc-
tion, prior stroke, prior transient ischemic attack, 
or prior use of other antiplatelet agents, angio-
tensin-converting–enzyme (ACE) inhibitors (over-
all and ramipril vs. other ACE inhibitors), statins 
(overall and atorvastatin, simvastatin, and prava-
statin), beta-blockers, calcium antagonists, antidia-
betic agents, angiotensin II–receptor blockers, cy-
clooxygenase-2 inhibitors, and anticoagulants.
Statistical Analysis
We estimated that 15,200 patients (7600 per group) 
and 1040 primary events would be necessary to 
detect a 20 percent relative risk reduction in the 
primary efficacy end point, with 90 percent pow-
er at the two-sided 0.05 significance level in this 
event-driven trial, assuming an annual event rate 
of 3.1 percent in the control group and 18 to 42 
months of follow-up. The primary efficacy out-
come was monitored with use of a Peto–Haybittle 
type of stopping rule based on the P value of the 
log-rank test. Two preplanned interim analyses 
were conducted by a statistician associated with 
the independent data and safety monitoring board. 
A two-sided type I error of 0.001 was used at each 
analysis. A type I error of 0.049 was preserved for 
the final analysis.
Data were analyzed on an intention-to-treat 
basis, with the inclusion of all patients according 
to their randomly assigned treatment group and 
the inclusion of outcomes occurring from random-
ization to a common study end date (August 29, 
2005). The time to the first occurrence of any 
event in the composite cluster was used for analy-
sis. Data on patients who did not reach the pri-
mary end point by the study end date were cen-
sored on the date of the patients’ last assessment 
visit. Death from noncardiovascular causes was 
treated as a competing event, and follow-up was 
censored on the date of death.
The primary efficacy of clopidogrel as com-
pared with placebo was assessed with the use of 
a two-sided log-rank test. The treatment effect as 
measured by the hazard ratio (the relative risk) 
and its associated 95 percent confidence interval 
was estimated with the use of the Cox propor-
tional-hazards model. Cumulative incidence event 
curves were also calculated. Statistical compari-
sons of the primary safety-event rates in the two 
treatment groups were performed with Pearson’s 
chi-square test. No adjustments for multiple com-
parisons were made. All analyses were performed 
with SAS software (version 8.0, SAS Institute).
R esult s
Characteristics of the Patients
A total of 15,603 patients from 32 countries and 
768 sites were enrolled between October 1, 2002, 
and November 14, 2003, in the CHARISMA trial. 
Of these patients, 7802 were assigned to receive 
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clopidogrel plus aspirin and 7801 were assigned 
to receive placebo plus aspirin. Treatment was per-
manently discontinued by 20.4 percent of the pa-
tients in the clopidogrel group, as compared with 
18.2 percent in the placebo group (P<0.001). A 
total of 4.8 percent of the patients in the clopido-
grel group and 4.9 percent of those in the placebo 
group discontinued treatment because of an ad-
verse event (P = 0.67).
The baseline characteristics of the patients in 
the trial have been described previously,12 and se-
lected features are listed in Table 2. The median 
age was 64 years; 29.8 percent of the patients were 
women. More than three quarters of the partici-
pants had established cardiovascular disease, as 
defined by the enrollment criteria, and most of 
the remaining patients had multiple atherothrom-
botic risk factors. On retrospective review of the 
enrollment information, 166 patients did not fall 
into either of these categories but were still con-
sidered in the broad population analysis.
Medications taken by the patients are shown 
in Table 3; these figures indicate the maximal 
frequency of use of each agent at any time dur-
ing the trial (with use assessed at baseline and 
at every follow-up visit). Almost all the patients 
(aside from those who died or dropped out) took 
aspirin and the study drug, and 10.2 percent also 
took open-label clopidogrel. Three quarters took 
a statin, and more than half took a beta-blocker. 
Nearly two thirds took an ACE inhibitor, and a 
quarter took angiotensin II–receptor blocking 
agents.
Efficacy End Points
Follow-up with respect to the primary efficacy end 
point (the first occurrence of myocardial infarc-
tion, stroke, or death from cardiovascular causes) 
was complete in 99.5 percent of the patients ran-
domly assigned to receive clopidogrel and aspirin 
and 99.6 percent of those randomly assigned to 
receive placebo and aspirin. The efficacy results 
are shown in Table 4. With a median of 28 months 
of follow-up, the rate of the primary event was 
6.8 percent in the clopidogrel group and 7.3 per-
cent in the placebo group (relative risk, 0.93; 95 
percent confidence interval, 0.83 to 1.05; P = 0.22) 
(Fig. 1A). The rate of the principal secondary ef-
ficacy end point (the first occurrence of myocar-
dial infarction, stroke, death from cardiovascular 
causes, or hospitalization for unstable angina, tran-
sient ischemic attack, or a revascularization pro-
cedure) was 16.7 percent in the clopidogrel group, 
as compared with 17.9 percent in the placebo group 
(relative risk, 0.92; 95 percent confidence interval, 
0.86 to 0.995; P = 0.04) (Fig. 1B).
Table 2. Baseline Characteristics.
Characteristic
Clopidogrel 
plus Aspirin 
(N = 7802)
Placebo 
plus Aspirin 
(N = 7801)
Demographic characteristics
Age — yr
Median 64.0 64.0
Range 39.0–95.0 45.0–93.0
Female sex — no. (%) 2316 (29.7) 2328 (29.8)
Race or ethnic group — no. (%)*
White 6272 (80.4) 6230 (79.9)
Hispanic 776 (9.9 ) 837 (10.7)
Asian 387 (5.0) 388 (5.0)
Black 252 (3.2) 234 (3.0)
Other 115 (1.5) 112 (1.4)
Inclusion subgroup
Documented vascular disease — no. (%) 6062 (77.7) 6091 (78.1)
Multiple risk factors — no. (%) 1659 (21.3) 1625 (20.8)
Neither subgroup — no. (%) 81 (1.0) 85 (1.1)
Selected clinical characteristics
Smoking status — no. (%)
Current 1571 (20.1) 1584 (20.3)
Former 3811 (48.9) 3802 (48.7)
Hypertension — no. (%) 5719 (73.3) 5764 (73.9)
Hypercholesterolemia — no. (%) 5748 (73.7) 5787 (74.2)
Congestive heart failure — no. (%) 469 (6.0) 457 (5.9)
Prior myocardial infarction — no. (%) 2672 (34.2) 2725 (34.9)
Atrial fibrillation — no. (%) 298 (3.8) 285 (3.7)
Prior stroke — no. (%) 1942 (24.9) 1895 (24.3)
Prior transient ischemic attack — no. (%) 938 (12.0) 926 (11.9)
Diabetes — no. (%) 3304 (42.3) 3252 (41.7)
Peripheral arterial disease — no. (%) 1760 (22.6) 1771 (22.7)
Prior percutaneous coronary intervention 
— no. (%)
1750 (22.4) 1804 (23.1)
Prior coronary-artery bypass grafting — 
no. (%)
1525 (19.5) 1554 (19.9)
Prior carotid endarterectomy 420 (5.4) 405 (5.2)
Prior peripheral angioplasty or bypass — 
no. (%)
879 (11.3) 858 (11.0)
Diabetic nephropathy — no. (%) 1006 (12.9) 1003 (12.9)
* Race or ethnic group was self-reported.
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Safety End Points
The rate of the primary safety end point (severe 
bleeding according to the GUSTO definition) was 
1.7 percent in the clopidogrel group and 1.3 per-
cent in the placebo group (relative risk, 1.25; 95 
percent confidence interval, 0.97 to 1.61; P = 0.09). 
The rate of moderate bleeding was 2.1 percent in 
the clopidogrel group, as compared with 1.3 per-
cent in the placebo group (relative risk, 1.62; 95 
percent confidence interval, 1.27 to 2.08; P<0.001). 
The rate of intracranial hemorrhage was similar 
in the two treatment groups (Table 4).
There was one documented nonfatal case of 
thrombotic thrombocytopenic purpura among the 
clopidogrel-treated patients; this patient died one 
month later from end-stage chronic obstructive 
pulmonary disease. No other serious adverse events 
were reported.
Subgroup Analyses
Several prespecified subgroup analyses classified 
patients according to their criteria for enrollment 
(Fig. 2). Patients who were enrolled because they 
had documented cardiovascular disease were des-
ignated “symptomatic,” whereas those who were 
enrolled because they had multiple atherothrom-
botic risk factors without documented cardiovas-
cular disease were designated “asymp tomatic.” 
(Some of the latter patients had a reported his-
tory of cardiovascular events, including 10.4 per-
cent with a prior myocardial infarction, 5.8 per-
cent with a prior stroke, 5.2 percent with a prior 
transient ischemic attack, 7.7 percent who had 
undergone a percutaneous coronary intervention, 
and 9.8 percent who had undergone coronary-
artery bypass grafting, although they did not meet 
the inclusion criteria for established cardiovascu-
lar disease as outlined in Table 1.)
Among the 3284 asymptomatic patients, there 
was a 20 percent relative increase in the rate of 
primary events with clopidogrel (6.6 percent, vs. 
5.5 percent with placebo; P = 0.20), whereas among 
the 12,153 symptomatic patients, there was a mar-
ginally significant reduction in the primary end 
point with clopidogrel (6.9 percent, vs. 7.9 percent 
with placebo; relative risk, 0.88; 95 percent con-
fidence interval, 0.77 to 0.998; P = 0.046). The in-
teraction term for this analysis, when the differ-
ential treatment response in asymptomatic and 
symptomatic patients was examined, was margin-
ally significant (P = 0.045).
In the subgroup of asymptomatic patients, there 
was a significant increase in the rate of death 
from all causes among the patients assigned to 
clopidogrel plus aspirin as compared with those 
assigned to placebo plus aspirin (5.4 percent vs. 
3.8 percent, P = 0.04) as well as an increase in the 
rate of death from cardiovascular causes among 
those assigned to clopidogrel (3.9 percent vs. 2.2 
percent, respectively; P = 0.01). In contrast, clopido-
grel had no significant effect on death from car-
diovascular causes in the symptomatic subgroup.
The rates of GUSTO-defined severe bleeding 
among the asymptomatic patients were 2.0 percent 
Table 3. Concomitant Medications.*
Medication
Clopidogrel
plus Aspirin 
(N = 7802)
Placebo
plus Aspirin 
(N = 7801)
no. of patients (%)
Aspirin 7775 (99.7) 7777 (99.7)
Study drug 7750 (99.3) 7760 (99.5)
Open-label clopidogrel 773 (9.9) 814 (10.4)
Diuretics 3757 (48.2) 3671 (47.1)
Nitrates 1812 (23.2) 1877 (24.1)
Calcium antagonists 2866 (36.7) 2879 (36.9)
Beta-blockers 4292 (55.0) 4344 (55.7)
Angiotensin II–receptor blockers 1990 (25.5) 2020 (25.9)
Ramipril 1387 (17.8) 1424 (18.3)
Other angiotensin-converting–enzyme 
inhibitors
3607 (46.2) 3612 (46.3)
Other antihypertensive agents 966 (12.4) 968 (12.4)
Statins 5991 (76.8) 6001 (76.9)
Atorvastatin 2777 (35.6) 2808 (36.0)
Simvastatin 2672 (34.2) 2695 (34.5)
Pravastatin 976 (12.5) 953 (12.2)
Fluvastatin 260 (3.3) 234 (3.0)
Lovastatin 273 (3.5) 283 (3.6)
Other statins 474 (6.1) 458 (5.9)
Other lipid-lowering agents 1114 (14.3) 1094 (14.0)
Fibrates 678 (8.7) 654 (8.4)
Binding resins 338 (4.3) 313 (4.0)
Nicotinic acid 277 (3.6) 262 (3.4)
Antidiabetic medications 3259 (41.8) 3237 (41.5)
Insulin 1360 (17.4) 1334 (17.1)
Thiazolidinediones 624 (8.0) 634 (8.1)
Other oral hypoglycemic agents 2677 (34.3) 2678 (34.3)
* These values indicate the maximal frequency of use of each agent at any time 
during the trial (assessed at baseline and at every follow-up visit).
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with clopidogrel and 1.2 percent with placebo 
(P = 0.07); the corresponding rates among the 
symptomatic patients were 1.6 percent and 1.4 
percent (P = 0.39). Although both these differenc-
es favored the placebo group, neither was signifi-
cant. The rates of GUSTO-defined moderate bleed-
ing among asymptomatic patients were increased 
(2.2 percent with clopidogrel and 1.4 percent with 
placebo, P = 0.08), as were the rates of moderate 
bleeding among symptomatic patients (2.1 percent 
and 1.3 percent, respectively; P<0.001). Again, both 
differences favored the placebo group, but this 
difference was significant only among the symp-
tomatic patients.
Discussion
In this trial of patients with established athero-
thrombotic disease or at high risk for such dis-
ease, there was no significant benefit associated 
with clopidogrel plus aspirin as compared with 
placebo plus aspirin in reducing the incidence of 
the primary end point of myocardial infarction, 
stroke, or death from cardiovascular causes. There 
was a moderate, though significant, benefit in re-
ducing the secondary composite end point of myo-
cardial infarction, stroke, death from cardiovascu-
lar causes, or hospitalization for unstable angina, 
transient ischemic attack, or revascularization.
The rate of severe bleeding was not signifi-
cantly greater with clopidogrel than with place-
bo, but a trend prompting concern was noted, 
and clopidogrel was associated with a significant 
increase in the rate of moderate bleeding. A total 
of 94 ischemic (secondary) end points were pre-
vented with clopidogrel, at a cost of 93 moderate 
or severe bleeding events.
The patients in our trial received evidence-based 
pharmacologic treatment, with frequent use of 
concomitant statins, ACE inhibitors, and other 
background medical therapy. The incidence of the 
primary end point with such therapy, as predict-
ed, was approximately 3 percent per year.
In the original, large-scale Clopidogrel versus 
Aspirin in Patients at Risk of Ischaemic Events 
(CAPRIE) trial,13 clopidogrel alone was found to 
Table 4. Composite and Individual Primary and Secondary End Points.
End Point
Clopidogrel 
plus Aspirin 
(N = 7802)
Placebo 
plus Aspirin 
(N = 7801)
Relative Risk 
(95% CI)* P Value
no. (%)
Efficacy end points
Primary efficacy end point 534 (6.8) 573 (7.3) 0.93 (0.83–1.05) 0.22
Death from any cause 371 (4.8) 374 (4.8) 0.99 (0.86–1.14) 0.90
Death from cardiovascular causes 238 (3.1) 229 (2.9) 1.04 (0.87–1.25) 0.68
Myocardial infarction (nonfatal) 146 (1.9) 155 (2.0) 0.94 (0.75–1.18) 0.59
Ischemic stroke (nonfatal) 132 (1.7) 163 (2.1) 0.81 (0.64–1.02) 0.07
Stroke (nonfatal) 150 (1.9) 189 (2.4) 0.79 (0.64–0.98) 0.03
Secondary efficacy end point† 1301 (16.7) 1395 (17.9) 0.92 (0.86–0.995) 0.04
Hospitalization for unstable angina, transient 
ischemic attack, or revascularization
866 (11.1) 957 (12.3) 0.90 (0.82–0.98) 0.02
Safety end points
Severe bleeding 130 (1.7) 104 (1.3) 1.25 (0.97–1.61) 0.09
Fatal bleeding 26 (0.3) 17 (0.2) 1.53 (0.83–2.82) 0.17
Primary intracranial hemorrhage 26 (0.3) 27 (0.3) 0.96 (0.56–1.65) 0.89
Moderate bleeding 164 (2.1) 101 (1.3) 1.62 (1.27–2.08) <0.001
* CI denotes confidence interval.
† The secondary efficacy end point was the first occurrence of myocardial infarction, stroke, death from cardiovascular 
causes, or hospitalization for unstable angina, a transient ischemic attack, or a revascularization procedure (coronary, 
cerebral, or peripheral).
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be superior to aspirin alone in reducing the risk 
of ischemic stroke, myocardial infarction, or death 
from vascular causes. However, there was debate 
as to whether P2Y12-receptor blockade provided 
uniform benefit. Since CAPRIE, four large clini-
cal trials have added to the body of evidence that 
supports the use of dual antiplatelet therapy in 
patients with acute coronary syndromes and in 
those undergoing percutaneous coronary inter-
vention.6-9 CHARISMA represented the logical next 
step of evaluation of the potential role of this 
approach in a broad population of patients with 
established vascular disease or multiple cardio-
vascular risk factors.
A subgroup analysis suggested that clopido-
grel was beneficial with respect to the primary 
efficacy end point in patients who were classified 
as symptomatic for the purposes of the trial (i.e., 
who were enrolled because of a documented his-
tory of established vascular disease). However, the 
P value for this association and the P value for 
the interaction between enrollment status and 
therapy were only marginally significant, sug-
gesting that this observation should be interpreted 
with caution, especially since this subgroup anal-
ysis was only one of several such analyses per-
formed. Furthermore, the risk of moderate or se-
vere bleeding in symptomatic patients was greater 
with clopidogrel than with placebo, although there 
was no significant increase in intracranial or fatal 
bleeding. Finally, as a practical matter, it is unclear 
how such a classification could be implemented 
clinically, since some patients in the asymp tomatic 
subgroup actually had a history of symptoms or 
cardiovascular events. The issue of whether dual 
antiplatelet therapy is beneficial in more specific 
subgroups of the population of patients with ath-
erothrombotic disease or risk will require further 
study.
On the other hand, the risk associated with 
dual antiplatelet therapy in the asymptomatic 
group was not anticipated. The excess fatalities 
in this subgroup and the heightened risk of bleed-
ing complications suggest that we should be cau-
tious about too quickly dismissing this unexpected 
finding as the play of chance. It is possible that 
established vascular disease represents a crude 
proxy for hyperactive platelets. If this concept is 
accepted, dual antiplatelet therapy would be anti-
cipated to be associated with greater efficacy and 
a lower rate of bleeding in the subgroup of symp-
tomatic patients. However, reduced basal platelet 
activity in asymptomatic patients would be ex-
pected to be a liability, increasing the risk of bleed-
ing complications, including possible hemorrhage 
into an arterial plaque. Whatever the explanation, 
it appears that until proven otherwise, clinicians 
should avoid dual antiplatelet therapy in patients 
without established vascular disease.
Recent studies of the genomics of myocardial 
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Figure 1. Cumulative Incidence of the Primary End Point (Panel A) 
and of the Secondary End Point (Panel B). 
Panel A shows cumulative incidence curves for the primary end point of 
myocardial infarction, stroke, or death from cardiovascular causes. Cumu-
lative incidence curves are displayed only up to 30 months because the un-
certainty of the estimates beyond this point becomes quite large. The num-
ber of patients followed after 30 months decreases rapidly to zero, and only 
21 primary efficacy events occurred after this time (13 in the clopidogrel 
group and 8 in the placebo group). Panel B shows cumulative incidence 
curves for the secondary end point, which included hospitalizations.
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infarction and atherosclerosis have revealed a 
marked difference among persons in the biologic 
basis of disease susceptibility. Whereas multiple 
genes have been demonstrated to confer suscep-
tibility to heart attack, little has been reported on 
the molecular determinants of atherosclerosis in 
humans.14 Atherosclerosis is far more common 
than are vascular events such as sudden death, 
heart attack, and stroke, which occur in a rela-
tively small subgroup of patients. One hypothesis 
that could be consistent with a benefit of dual 
antiplatelet therapy in symptomatic patients (those 
with established vascular disease) is that this 
group has already shown a predisposition to arte-
rial plaque rupture, fissure, or erosion. That dual 
antiplatelet therapy is best used in patients who 
are most liable to have such arterial injury appears 
to be a worthy hypothesis for prospective evalu-
ation.
In summary, the combination of clopidogrel 
plus aspirin was not significantly more effective 
than aspirin alone in reducing the rate of myo-
cardial infarction, stroke, or death from cardio-
vascular causes among patients with stable car-
diovascular disease or multiple cardiovascular 
risk factors. Furthermore, the risk of moderate-to-
severe bleeding was increased. Our findings do 
not support the use of dual antiplatelet therapy 
across the broad population tested. There was a 
potential benefit in symptomatic patients (those 
with established vascular disease); this finding re-
quires further study. Data on mortality rates sug-
gest that dual antiplatelet therapy should not be 
used in patients without a history of established 
vascular disease.
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